DOCSLIB.ORG

Effects of Trihexyphenidyi on Schedule-Induced Alcohol Drinking

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Trihexyphenidyi on Schedule-Induced Alcohol Drinking drinkometers, and all programming Effects of trihexyphenidyI on and recording were computer controlled. Number of licks and schedule-induced alcohol drinking by rats* barpresses were printed out at I-min intervals. PROCEDURE Daily 100-min experimental sessions J. D. KEEHN were run in which bar presses were Atkinson College, York University, Toronto, Ont., Canada reinforced with 45-mg Noyes pellets at fixed intervals of not less than 1 min Three rats from the Maudsley reactive strains and three rats from the (FI 1 min). For the first three sessions Maudsley nonreactive strain were trained to barpress with food reinforcement (Sessions 12-14), a 2.5% (v/v) alcohol scheduled at fixed intervals of 1 min. With various alcohol concentrations, solution was in the drinking tube. The schedule-induced licking was higher in the nonreactive animals but there was concentration was increased to 3.5% little difference in intake between the strains. Injections of trihexyphenidyl (Session 15), 4.5% (Session 16), 6.5% attenuated alcohol consumption by all animals, with 3.0 mg/kg being the most (Sessions 17-19), 8.5% (Session 20). effective dose. This concentration was continued to the end of the experiment for Animals Chemical control of alcoholism in Maudsley nonreactive strain raised at R1 and R3; the concentration was man has concentrated on drugs, such the Uni versi ty of Birmingham, raised to 10.5% for the other animals as disulf'trum, that, when combined England, were used. They were from Session 21, onward. Beginning with alcohol, produce an aversive maintained at approximately 80% of with Session 18, the animals were effect (Weissman & Koe, 1969). Such their free-feeding weights over the deprived of fluid for 20 h before each drugs are not without danger and, also, course of the experiment. Actual mean experimental session. require abstinence from alcohol when running weights were: Rl, 224 g; R2, Artane injections (IP) began with they are taken. This requirement no 240 g; R3, 217 g; r4, 224 g; r5, 184 g; Session 24, in doses of 0.0, 1.5, 3.0, longer seems to be necessary in the ro, 202 g. Immediately prior to the and 4.5 mg/kg in a Latin-square treatment of alcoholism (Pattison present experiment, they had been design, with two drug-free sessions et al, 1968), and, in addition, patients exposed for 11 days to the between each dose. The orders in wishing to drink, simply refrain from ex perimental conditions described which the animals received the taking their disulf'trum doses. below but with water as the test fluid. respective doses were: Rl and r4, An alternative way of reducing 1234; R2 and r5, 2341; R3 and r6, drinking is by anticholinergic drugs. APPARATUS 3412. The 0.0 dose was 0.5 ml of These were first used to block Ex perimen tal chambers were six distilled water; all other doses were in chemically elicited drinking Lehigh-Valley two-bar rat boxes, this medium and volume and were (Grossman, 1962; Stein, w 1963) but Type 1417, enclosed in separate given immediately before an were later shown to attenuate sound -ins ulated chambers. Each box experimental session. pala tability-induced (Matsunaga & contained a single bar that activated RESULTS Keehn, 1969) and schedule-induced automatic programming and recording Figure 1 shows the numbers of licks (Burks & Fisher, 1970; Keehn & equipment when pressed with a force emitted by each of the animals in each Nagai, 1969) polydipsia. In all these of at least 25 g (.245 N). In place of of the 12 predrug sessions. The higher cases, the fluid consumed was water. the second bar was the spout of a rates of licking by the nonreactive The attenuation of rats' consumption drinking tube that contained alcohol animals, r4, r5, and ro, does not of weak saccharin-sweetened alcohol solutions of various concentrations as necessaril y represent a greater solutions by the anticholinergic drug described below. Licks at the tube preference for alcohol by this strain trihexyphenidyl has been reported by were monitored via Lehigh-Valley because they had already licked at a Keehn & Matsunaga (1971), who also showed an optimum dose-response effect with 3.0 mg/kg of the drug in th e case of sched ule-ind uced ......• consumption of water. The present report is of the effects of trihex yphenidyl (Artane) on schedule-induced drinking of strong unsweetened alcohol solutions by rats . .... that showed different levels of schedule-induced drinking of water. SUBJECTS Six 130-day-old male rats, three •.... from the 39th generation of the Maudsley reactive strain and three • R6 from the 39th generation of the • R4 RS *This study was conducted in the R1 Psychological Laboratories of the University o ... .. ~ .. ·.o · .... o .. ··0 · of Birmingham through tbe courtesy of R20""" '~- -o-~ -<>---0" Professor P. L. Broadhurst. Tbe researcb was . , supported partly by tbe Addiction Researcb 12-SESSIONS--~--------23 Foundation of Ontario and partly by tbe Medical Research Council of Canada through Grant MA-4528. The Fig_I. Number of licks per tOO-min session by reactive (1, 2, 3) and trihexypbenidyl was kindly supplied by the Lederle Division of Cyanamid of Canada nonreactive (4, 5,6) Maudsley rats food-reinforced at I-min intervals. See text Ltd. and Table 1 for alcohol concentrations. 20 Psychon. Sci., 1972, Vol. 29 (1 ) Table 1 towards a table edge. Pre drug Alcohol Solution Intakes (Milliliters) Effects of Mane on numbers of Session 15 16 17 18 19 20 21 22 23 barpresses and licks and on the percentage of interpellet intervals in Concentration 3.5 4.5 6.5 6.5 6.5 8.5 10.5 10.5 10.5 (Percent) which drinking failed to occur are shown in Table 2. The drug seemed to R1 10 13 5 21 7 8 10* 8* 10* R2 8 14 5 13 15 15 20 7 8 have no systematic effect on R3 10 10 8 11 10 17 10* 8* 8* barpressing, but, for most animals, both measures of drinking were r4 10 13 8 11 7 5 6 7 7 r5 21 19 12 13 12 12 9 7 7 maximally affected by the 3.0 mg/kg r6 21 10 8 7 6 7 3 3 5 dose of the drug. Cumulative records of licking at the 0.0 and 3.0 mg/kg *Alcohol concentration 8.5% (v/v) doses are shown for all animals in Figs. 2 and 3. (Note that the ordinates of Table 2 the figures differ by a factor of 5.) The Total Barpresses, Licks, and Percent of Intervals in Which Drinks Were Not Taken According to Drug Dose figures show reduced licking by all animals under the drug and, also, Measure Dose Rl R2 R3 r4 r5 r6 distinctly different patterns of 0.0 524 492 1,235 1,254 2,512 3,373 drinking by members of the two 1.5 239 370 926 1,369 1,459 3,391 strains; the nonreactives tended to Licks 3.0 269 267 915 1,050 1,600 2,529 take small and frequent drinks, 4.5 431 415 1,047 706 1,620 3,971 whereas the reactives drank 0.0 87 83 72 58 1 5 infrequently but in fairly regular Percent 1.5 82 92 65 62 8 6 bursts. Intervals 3.0 91 69 76 64 31 35 DISCUSSION Missed 4.5 83 59 72 66 7 1 As with schedule-induced water 0.0 3,720 7,608 3,755 2,455 3,799 1,165 drinking (Keehn & Matsunage, 1971), 1.5 5,501 4,194 3,494 2,295 2,886 1,176 schedule-induced alcohol drinking by Barpresses 3.0 8,610 6,961 2,032 2,732 3,700 1,148 rats was attenuated by injections of 4.5 3,670 9,007 2,297 1.907 4,903 1,415 trihexyphenidyl, with 3.0 mg/kg appearing again to be the optimum higher rate for water than had the alcohol intakes were generally higher dose. The degree of attenuation, about reactives, the respective totals being in the reactive animals (see Table 1), 32% across all animals, approximated 6,600, 5,511, and 10,299 licks in a even though their licks were fewer. At that previously obtained with wa~1 prealcohol session, against 1,338, 166, the highest dose levels, animals were al though alcohol intakes in the and 1,055 by Rl, R2, and R3, generally flaccid at the end of absence of the drug were only about respectively. In fact, beginning with experimental sessions and exhibited one-quarter of those of water. the session in which they were first impaired placing responses in that only Although several studies have shown run wa ter-deprived (Session 18), one paw was raised as they were nosed that trihexyphenidyl and other Alcohol (') Artane (mo/ko) Alcohol (1J 10.5 0.0,3.0 R1 8.5 ArtcwIe (mg/kg) 10.5 0.0 . 3D 10.5 ,/" R2 10.5 ../ l I aD R3 8.5 ../ re :,J' / ,/ '" .- R3 ./ / J'; '" .. ...J 0.0 j r-- f" - R2 r 1.0 R1 ~ I" e ' ./"' - '.0 ./ ~ , .-JI' r- REINfORCEMENTS ~ 10 -1 RE INFORCEMENT Fig. 2. Cumulative licking records of Maudsley nonreactive rats under 0.0 Fig. 3. Cumulative licking records of Maudsley reactive rats under 0.0 and and 3.0 mg/kg Artane doses. 3.0 lng/kg Mane doses. Note that the ordinate scale is one-rUth that of Fig. 2. Psychon. Sci., 1972, Vol. 29 (1) 21 anticholinergic drugs attenuate fluid (nonreactives) or do not (reactives) of schedule-induced polydipsia by trihexyphenidyl.
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Ketamine As a General Anesthesia Adjunct Michaela Wilcox, DNP
    Ketamine as a General Anesthesia Adjunct Michaela Wilcox, DNP (c), RN Dept. of Nurse Anesthesia, Moffett & Sanders School of Nursing, Samford University Structured Abstract Background Ketamine is a unique anesthetic agent with both anesthetic and analgesic properties. Ketamine is primarily a N-Methyl-D-Aspartic acid (NMDA) antagonist that also works on glutamine, nicotinic, muscarinic, monoaminergic and opioid receptors. The uses of ketamine are numerous and include treatment of chronic pain, acute pain, depression, as a multimodal pain adjunct, opioid-sparing agent and as an adjunct in enhanced recovery after surgery (ERAS) protocols. A 49-year-old female presented for a lumbar lateral interbody fusion extreme, anterior lumbar spine arthrodesis L3/4 with revision and instrumentation. Based on the surgical need for both sensory and motor nerve monitoring intraoperatively, the anesthetic plan included minimal sevoflurane, succinylcholine for induction and a propofol intravenous (IV) infusion with boluses of ketamine to maintain unconsciousness. A bispectral index (BIS) monitor (Aspect Medical Systems, Natick, MA) was placed on the patient’s forehead prior to induction and utilized intraoperatively to maintain a goal of 40-60. General anesthesia was achieved with fentanyl 100 mcg, lidocaine 100 mg, propofol 200 mg, ketamine 50 mg and succinylcholine 160 mg IV. Laryngoscopy was successfully performed using a McGrath MAC video laryngoscope (Medtronic, Minneapolis, MN). Following induction, a propofol IV infusion was initiated and sevoflurane maintained at 0.3 minimum alveolar concentration. Ketamine 10 mg IV was administered every hour. Upon conclusion of the procedure, the patient was extubated and transported to postoperative recovery unit, where she had no complaints of nausea, vomiting or pain.
    [Show full text]
  • (Antimuscarinic) Drugs?
    © July - August 2018 How well do you know your anticholinergic (antimuscarinic) drugs? nticholinergic drugs, prescribed for a variety of clini- Acal conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “an- timuscarinics,” such drugs specifically block muscarinic receptors for acetylcholine (ACh).1 Muscarinic ACh recep- tors are important in the parasympathetic nervous system that governs heart rate, exocrine glands, smooth muscles, clude drugs whose active metabolites are potent- as well as brain function. In contrast, nicotinic ACh recep- ly antimuscarinic,5 or which often cause typical tors stimulate contraction of striated muscles. This Letter is AC adverse effects such as dry mouth or urinary intended to remind clinicians of commonly used drugs that retention.6 People taking antihistamines, antide- have anticholinergic (AC), or technically, antimuscarinic pressants, antipsychotics, opioids, antimuscarinic properties, and of their potential adverse effects. inhalers, or many other drugs need to know that Beneficial and harmful effects of anticholinergic drugs have blockade of ACh receptors can cause bothersome been known for centuries. In Homer’s Odyssey, the nymph or even dangerous adverse effects (Table 3). pharmacologist Circe utilized central effects of atropinics Subtle and not-so-subtle toxicity in the common plant jimson weed (Datura stramonium) to cause delusions in the crew of Odysseus. Believing they Students often learn the adverse effects of anticho- had been turned into pigs, they could be herded.2 linergics from a mnemonic, e.g.: “Blind as a bat, Sometimes a drug is recommended specifically for its an- mad as a hatter, red as a beet, hot as a hare, dry as ticholinergic potency.
    [Show full text]
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • Anesthesia and Analgesia in Laboratory Animals
    GUIDELINES ON ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS University of South Florida provides the following guidelines for use by IACUC-certified faculty and staff. CONTENTS PAGE A. Background……………………………………………………….…………………………… 1 B. Definitions....……………………………………………………..…………………………….. 2 C. General Considerations……………………………………….,…………………………….. 3 D. Controlled Substances……………………………………….……………………………… 3 E. Pre-Anesthetic Treatments………………………………….………………………………. 4 F. General Anesthetics………………………………………….………………………………. 4 G. Neuromuscular Blocking Agents………………………….……………………………….. 5 H. Monitoring Anesthesia…………………………………….…………………………………. 6 I. Analgesics……………………………………………………………………………………… 7 J. Comments regarding Anesthetics and Analgesics……………………………………... 7 REFERENCE TABLES PAGE I. Signs of Pain and Distress in Laboratory Animals………………………………………… 10 II. Commonly Used Anesthetics and Analgesics for Mice….………..…...….………...…… 11 III. Commonly Used Anesthetics and Analgesics for Rats……………………………...…… 12 IV. Commonly Used Anesthetics and Analgesics for Gerbils……….……………..…….. 13 V. Commonly Used Anesthetics and Analgesics for Hamsters…….……………..……. 14 VI. Commonly Used Anesthetics and Analgesics for Guinea Pigs….…………….….……. 15 VII. Commonly Used Anesthetics and Analgesics for Rabbits.……...…………….………… 16 VIII. Commonly Used Anesthetics and Analgesics for Dogs.…………………….…………… 17 IX. Commonly Used Anesthetics and Analgesics for Cats.……………………..…………… 18 X. Commonly Used Anesthetics and Analgesics for Pigs ..……………..….………………..19 XI. Commonly Used Anesthetics and Analgesics
    [Show full text]
  • Metered-Dose Inhalers (Mdis): Anti-Cholinergic Drugs
    Texas Vendor Drug Program Drug Use Criteria: Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Cholinergic Drugs Publication History 1. Developed January 1995. 2. Revised April 2021; March 2019; March 2017; November 2015; March 2014; August 2012; June 2012; October 2010; January 2008; January 2003; January 2002; January 2001; March 2000; January 2000; February 1999; February 1998; February 1997; August 1995. Notes: All criteria may be applied retrospectively. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: • Drug Information Service, UT Health San Antonio. • The College of Pharmacy, The University of Texas at Austin 1 1 Dosage 1.1 Adults Ipratropium (Atrovent®), a short-acting, inhalational anticholinergic agent, is FDA- approved to manage bronchospasm associated with chronic bronchitis and emphysema, collectively known as chronic obstructive pulmonary disease (COPD). Ipratropium is considered a second-line agent in the treatment of asthma as the bronchodilatory effects seen with ipratropium are less than those seen with beta- adrenergic drugs. While not FDA approved, the Expert Panel 3 guidelines from the National Heart Lung and Blood Institute document benefit when multiple ipratropium doses are administered adjunctively with beta2-agonists in the emergency department to manage more severe acute asthma exacerbations, and the Global Initiative for Asthma (GINA) guidelines state that ipratropium may be considered an alternative bronchodilator in patients who experience adverse effects to short-acting beta2-agonists (e.g., tachycardia, arrhythmia, tremor).
    [Show full text]
  • CONTRAINDICATIONS ------Pediatric Patients (486 on DETROL LA, 224 on Placebo) Is Available
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Controlled Narrow-Angle Glaucoma: use caution in patients being These highlights do not include all the information needed to use Detrol® treated for narrow-angle glaucoma. (5.3) LA safely and effectively. See full prescribing information for Detrol LA. • Myasthenia Gravis: use caution in patients with myasthenia gravis. (5.6) • QT Prolongation: Consider observations from the thorough QT study in ® Detrol LA (tolterodine tartrate extended release capsules) clinical decisions to prescribe DETROL LA to patients with a known For oral administration history of QT prolongation or to patients who are taking Class IA (e.g., Initial U.S. Approval: December 2000 quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications (5.7) ----------------------------INDICATIONS AND USAGE--------------------------- Detrol LA is an antimuscarinic indicated for the treatment of overactive ------------------------------ADVERSE REACTIONS------------------------------- bladder with symptoms of urge urinary incontinence, urgency, and frequency. The most common adverse reactions (incidence >4% and >placebo) were dry (1) mouth , headache, constipation and abdominal pain. (6.1) ----------------------DOSAGE AND ADMINISTRATION----------------------- • 4 mg capsules taken orally once daily with water and swallowed To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at whole. (2.1) 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. • 2 mg capsules taken orally once daily with water and swallowed whole in the presence of: ------------------------------DRUG INTERACTIONS------------------------------- o mild to moderate hepatic impairment (Child-Pugh • Potent CYP3A4 inhibitors: Co-administration may increase systemic class A or B) (2.2) exposure to DETROL LA. Reduce DETROL LA dose to 2 mg once o severe renal impairment [Creatinine Clearance (CCr) daily.
    [Show full text]
  • Anticholinergic Drugs Toxicity
    Prescription drug toxicity Anticholinergic drug toxicity Anticholinergic syndrome is produced by the inhibition of cholinergic neurotransmission at muscarinic receptor sites. It commonly follows the ingestion of a wide variety of prescription and over-the-counter medications. Signs and symptoms Clinical manifestations are caused by CNS effects, peripheral nervous system effects, or both. Common manifestations are as follows: Flushing Dry skin and mucous membranes Mydriasis with loss of accommodation Altered mental status Fever Additional manifestations include the following: Sinus tachycardia Decreased bowel sounds Urinary retention Hypertension Pathophysiology Substances with anticholinergic properties competitively antagonize acetylcholine muscarinic receptors; this predominantly occurs at peripheral (eg, heart, salivary glands, sweat glands, GI tract, urinary tract) postganglionic parasympathetic muscarinic receptors. Anticholinergic substances minimally compete with acetylcholine at other sites (eg, autonomic ganglia). Central nervous system manifestations result from central cortical and subcortical muscarinic receptor antagonism. The degree of CNS manifestation is related to the drug's ability to cross the blood-brain barrier. 1 Agents with anticholinergic properties are as follows: Anticholinergics o Atropine, scopolamine Antihistamines o Chlorpheniramine o Cyproheptadine o Diphenhydramine o Promethazine Antipsychotics o Chlorpromazine o Clozapine o Thioridazine Antispasmodics o Clidinium o Hyoscyamine o Propantheline
    [Show full text]
  • (Cholinergic Antagonists) (Anticholinergic ) (Cholinergic
    Parasympathlytic (Cholinergic antagonists) (Anticholinergic ) (Cholinergic Blockers) A- antimuscarinic agents (Muscarinic Antagonists): " Agents with high binding affinity for muscarinic receptors but no intrinsic activity. Pharmacologic effects opposite of the muscarinic agonists. " Competitive (reversible) antagonists of ACh " Antagonistic responses include: decreased contraction of GI and urinary tract smooth muscles, dilation of pupils, reduced gastric secretion, decreased saliva secretion. A- antimuscarinic agents (Muscarinic Antagonists): 1-Atropine (belladonna alkaloid) " (Competitive inhibitors) . -bind to muscarinic receptors and prevent Ach binding. " reversible blockade of ACh at muscarinic receptors by competitive binding! -reversal effect of atropine by increasing ACh or agonist ----> decreased blockade -atropine is central & peripheral muscarinic blocker. Muscarinic receptor blockade does not interfere with transmission at autonomic ganglionic sites, the adrenal medulla, or skeletal muscle fibers. Sympathetic adrenergic functions are not affected. X X MUSCARINIC RECEPTOR BLOCKADE ALLOWS SYMPATHETIC DOMINANCE IN DUAL INNERVATED ORGANS X Atropine actions "Eye: *mydriasis *unresponsiveness to light *cycloplegia *increase IOP " GIT: reduce activity of GIT. " Urinary system: reduce hyper motility. " Cardiovascular system: at low dose bradycardia at high dose tachycardia " Secretions: reduce secretions Therapeutic uses of atropine 1-Ophthalmic: Ophthalmologic examinations. mydriatic & cycloplegic effects. 2-antispasmotic agent
    [Show full text]
  • Anticholinergic Pocket Reference Card
    Anticholinergic Pocket Reference Card Because so many drugs have anticholinergic properties—and many of these are contained in over-the-counter products—anticholinergics are used by many older adults, including about 1/3 of people with dementia.1,2 The elderly are more sensitive to anticholinergic adverse effects, and people with dementia have a high risk of adverse cognitive and psychiatric effects from these drugs.3,4 Adverse effects attributed to anticholinergics include sedation, confusion, delirium, constipation, urinary retention, dry mouth, dry eyes, blurred vision, photophobia, tachycardia, decreased sweating, increased body temperature, falls, and others.5 Some evidence suggests that anticholinergics contribute to behavioral disturbances and psychosis in dementia.3 The purpose of this reference card is to help clinicians reduce anticholinergic use by vulnerable elders, especially those with cognitive impairment. Tapering may be necessary to prevent withdrawal symptoms when discontinuing potent anticholinergics that have been used chronically.2 The following lists medications with known anticholinergic effects by therapeutic use. The list is not all-inclusive, but includes many commonly used anticholinergics. Clinicians might want to especially consider the risk benefit balance of tricyclic antidepressants, immediate-release oxybutynin, GI antispasmodics, and sedating antihistamines, as these drugs are not recommended for vulnerable elders if alternative treatments are available.7 Antihistamines / Allergy / Bladder Antispasmodics Cough
    [Show full text]
  • The Anticholinergic Impregnation Scale: Towards The
    Therapie (2017) 72, 427—437 Available online at ScienceDirect www.sciencedirect.com CLINICAL PHARMACOLOGY The anticholinergic impregnation scale: Towards the elaboration of a scale adapted to prescriptions in French psychiatric settings L’échelle d’imprégnation anticholinergique : vers l’élaboration d’une échelle adaptée aux prescriptions en milieu psychiatrique franc¸ais a,b b,c,∗ Jeanne Briet , Hervé Javelot , c d Edwige Heitzmann , Luisa Weiner , c e Catherine Lameira , Philippe D’Athis , e a,b Marie Corneloup , Jean-Louis Vailleau a Pharmacy service, CHS de La Chartreuse, 21000 Dijon, France b PIC network (Psychiatrie Information Communication), EPSM Lille-Métropole, 59487 Armentières, France c Établissement public de santé Alsace Nord, 67170 Brumath, France d Psychiatry II and Inserm unit 1114, university hospital of Strasbourg, 67000 Strasbourg, France e Service of biostatistics and medical informatics, CHU de Dijon, 21000 Dijon, France Received 6 June 2016; accepted 23 December 2016 Available online 17 February 2017 KEYWORDS Summary Anticholinergics; Purpose. — Some drugs have anticholinergic activity and can cause peripheral or central side Anticholinergic drug effects. Several scales exist to evaluate the potential anticholinergic effect of prescribed drugs scale; but: (i) they are validated in the elderly and mainly assess the cognitive side effect of treat- Psychiatry ments; (ii) they do not concern some of the drugs frequently used in clinical psychiatry in France. The aim of our study is to develop a new scale, the anticholinergic impregnation scale (AIS), with drugs used in France and based on an assessment of the drugs used against peripheral anticholinergic adverse effects. ∗ Corresponding author. Clinical pharmacy service, Établissement public de santé Alsace Nord (EPS Alsace Nord), 141 avenue de Strasbourg, 67170 Brumath, France.
    [Show full text]